AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12433513 — intervention group
Group type: EXPERIMENTAL
Intervention: Indo-Mediterranean diet rich in whole grains, fruits, vegetables, walnuts, and almonds
Number of subjects: 1000
Study 12433513 — intervention group
Group type: COMPARATOR
Intervention: Local diet similar to the step I National Cholesterol Education Program (NCEP) prudent diet
Number of subjects: 1000
Study 10369282 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative/postoperative Impact
Number of subjects: 136
Study 10369282 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Impact
Number of subjects: 136
Study 10369282 — intervention group
Group type: COMPARATOR
Intervention: Postoperative standard formula
Number of subjects: 136
Study 10369282 — intervention group
Group type: COMPARATOR
Intervention: Preoperative/postoperative standard formula
Number of subjects: 136
Study 10369282 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact
Number of subjects: 136
Study 7500456 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C
Number of subjects: 68
Study 7500456 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C and BCG (alternating therapy)
Number of subjects: 68
Study 2310248 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.1 mg/kg up to 10 mg) intravenously three to five minutes before aortic cross‐clamping
Number of subjects: 40
Study 2310248 — intervention group
Group type: COMPARATOR
Intervention: Control (no verapamil)
Number of subjects: 40
Study 382148 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg, 20 mg, or 50 mg of domperidone orally
Number of subjects: 156
Study 382148 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg domperidone intravenously
Number of subjects: 156
Study 382148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 30641712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50000 IU) supplement weekly
Number of subjects: 50
Study 30641712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28068951 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 175
Study 25788397 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐switched ruby laser (694nm)
Number of subjects: 11
Study 25788397 — intervention group
Group type: COMPARATOR
Intervention: Ablative CO2 fractional laser (10,600nm)
Number of subjects: 11
Study 23676191 — intervention group
Group type: EXPERIMENTAL
Intervention: VIABAHN endoprosthesis
Number of subjects: 148
Study 23676191 — intervention group
Group type: COMPARATOR
Intervention: bare nitinol stent
Number of subjects: 148
Study 21835835 — intervention group
Group type: EXPERIMENTAL
Intervention: Research nurse weight estimate using Seca 835‐2 digital paediatric scales
Number of subjects: 156
Study 21835835 — intervention group
Group type: COMPARATOR
Intervention: Parental weight estimate using usual home scales
Number of subjects: 156
Study 19149522 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once-daily
Number of subjects: 0
Study 19149522 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg twice-daily
Number of subjects: 0
Study 19149522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17224540 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic learning group
Number of subjects: 130
Study 17224540 — intervention group
Group type: COMPARATOR
Intervention: Solo learning group
Number of subjects: 130
Study 14698689 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerosity comparison with size and ratio manipulation
Number of subjects: 0
Study 14698689 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison performance with controlled surface area
Number of subjects: 0
Study 14698689 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation between comparison performance and verbal counting knowledge
Number of subjects: 0
Study 14500259 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 105
Study 14500259 — intervention group
Group type: COMPARATOR
Intervention: High-concentration oxygen therapy
Number of subjects: 105
Study 9923765 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized history and neurologic examination, laboratory tests (complete blood cell count, serum albumin level, vitamin B12 level, and T-lymphocyte subsets), and electrophysiologic testing of sural, tibial, and ulnar nerves
Number of subjects: 251
Study 7897127 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary revascularization in 1991
Number of subjects: 600
Study 7897127 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary revascularization in 1986-1987
Number of subjects: 600
Study 2311881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen (3 liter/min)
Number of subjects: 56
Study 2311881 — intervention group
Group type: COMPARATOR
Intervention: Room air (control)
Number of subjects: 56
Study 7426272 — intervention group
Group type: EXPERIMENTAL
Intervention: Young smokers
Number of subjects: 0
Study 7426272 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly smokers
Number of subjects: 0
Study 7426272 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (young and elderly)
Number of subjects: 0
Study 30691328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led telehealth
Number of subjects: 0
Study 30691328 — intervention group
Group type: COMPARATOR
Intervention: Nurse-led telehealth
Number of subjects: 0
Study 30420324 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose voclosporin (23.7 mg, twice daily)
Number of subjects: 265
Study 30420324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose voclosporin (39.5 mg, twice daily)
Number of subjects: 265
Study 30420324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 29273661 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (6 messages per week targeting blood pressure control, medication adherence, physical activity, smoking cessation, glucose monitoring, and lifestyle recommendations)
Number of subjects: 1300
Study 29273661 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 1300
Study 25421482 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHG) body wash, frequent use reported by 360 participants (56.3%)
Number of subjects: 1706
Study 24429379 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet access (IA) group
Number of subjects: 171
Study 24429379 — intervention group
Group type: COMPARATOR
Intervention: Non-Internet access (NIA) group
Number of subjects: 171
Study 22936018 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration
Number of subjects: 60
Study 22936018 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI (without thrombus aspiration)
Number of subjects: 60
Study 19164322 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily) for 6 months
Number of subjects: 80
Study 17882570 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional cycle of oral steroids
Number of subjects: 0
Study 17882570 — intervention group
Group type: COMPARATOR
Intervention: Control group with no further treatment
Number of subjects: 0
Study 14630595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingzhi (1.1g single dose)
Number of subjects: 10
Study 14630595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingzhi (3.3g acute dose)
Number of subjects: 10
Study 14630595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingzhi (0.72 g/d for 10 days)
Number of subjects: 10
Study 14630595 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 10
Study 12588694 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fruit and Vegetable (FV) diet
Number of subjects: 122
Study 12588694 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat diet
Number of subjects: 122
Study 12588694 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Low-Fat/High-FV diet
Number of subjects: 122
Study 12588694 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 122
Study 9686497 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class II (n=23)
Number of subjects: 93
Study 9686497 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class III (n=26)
Number of subjects: 93
Study 9686497 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels in patients with congestive heart failure class IV (n=14)
Number of subjects: 93
Study 9686497 — intervention group
Group type: COMPARATOR
Intervention: Plasma adrenomedullin levels in normal subjects (n=30)
Number of subjects: 93
Study 9686497 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adrenomedullin levels after treatment
Number of subjects: 93
Study 8294707 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 218
Study 8294707 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 218
Study 8294707 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 218
Study 30803197 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (4 sessions)
Number of subjects: 57
Study 30803197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 57
Study 28741652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine without morphine and postoperative rectus sheath bupivacaine
Number of subjects: 131
Study 28741652 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal bupivacaine with morphine and postoperative rectus sheath saline
Number of subjects: 131
Study 26109470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (HbA1c <7.0%, blood pressure ≤135/85 mmHg, total cholesterol ≤3.5 mmol/L)
Number of subjects: 424
Study 26109470 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 424
Study 24295838 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tutorial (10-minute duration)
Number of subjects: 40
Study 24295838 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative consultation)
Number of subjects: 40
Study 24295838 — intervention group
Group type: EXPERIMENTAL
Intervention: Video tutorial
Number of subjects: 40
Study 23018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 15, 50, 100 or 150 mg once daily for 28 days (young men)
Number of subjects: 52
Study 23018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg and then 100 mg once daily for 14 days (elderly subjects)
Number of subjects: 52
Study 23018531 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat >50 mg/day
Number of subjects: 52
Study 23018531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (young men)
Number of subjects: 52
Study 23018531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (elderly subjects)
Number of subjects: 52
Study 19380692 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated software algorithm for volumetric measurement of pulmonary nodules
Number of subjects: 101
Study 16952511 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 29
Study 16952511 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 29
Study 16952511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 15246797 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM program (E1 and E2)
Number of subjects: 73
Study 15246797 — intervention group
Group type: COMPARATOR
Intervention: Control groups (C1 and C2)
Number of subjects: 73
Study 11739201 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month cyclosporine prophylaxis
Number of subjects: 162
Study 11739201 — intervention group
Group type: COMPARATOR
Intervention: 6-month cyclosporine prophylaxis
Number of subjects: 162
Study 9404251 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing
Number of subjects: 27
Study 9404251 — intervention group
Group type: COMPARATOR
Intervention: DDD pacing
Number of subjects: 27
Study 9404251 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 27
Study 8480264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (PCA-M)
Number of subjects: 0
Study 8480264 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled intravenous narcotic analgesia (PCA-M) alone
Number of subjects: 0
Study 3099651 — intervention group
Group type: EXPERIMENTAL
Intervention: OK‐432 i.v. plus Tegafur
Number of subjects: 172
Study 3099651 — intervention group
Group type: EXPERIMENTAL
Intervention: PSK oral application plus Tegafur
Number of subjects: 172
Study 3099651 — intervention group
Group type: COMPARATOR
Intervention: Tegafur oral administration only
Number of subjects: 172
Study 3099651 — intervention group
Group type: EXPERIMENTAL
Intervention: BRM therapy (OK‐432 and PSK)
Number of subjects: 172
Study 29977281 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Practice (PP)
Number of subjects: 30
Study 29977281 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational Practice (OP)
Number of subjects: 30
Study 29977281 — intervention group
Group type: COMPARATOR
Intervention: No Practice (NP) Control
Number of subjects: 30
Study 26982618 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of H. sabdariffa calyx powder
Number of subjects: 40
Study 26982618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 24118206 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation (ONS)
Number of subjects: 11
Study 24118206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 22394534 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily TERT of 6‐12 hr
Number of subjects: 22
Study 22394534 — intervention group
Group type: COMPARATOR
Intervention: Daily TERT of 12‐16 hr
Number of subjects: 22
Study 20035000 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage procedure (Group 2)
Number of subjects: 20
Study 20035000 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cystectomy (Group 1)
Number of subjects: 20
Study 19294859 — intervention group
Group type: EXPERIMENTAL
Intervention: Component compatibility group
Number of subjects: 120
Study 19294859 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy group
Number of subjects: 120
Study 19294859 — intervention group
Group type: COMPARATOR
Intervention: Pieces group
Number of subjects: 120
Study 19294859 — intervention group
Group type: COMPARATOR
Intervention: Xuesaitong group
Number of subjects: 120
Study 15986589 — intervention group
Group type: EXPERIMENTAL
Intervention: Schellong test (ST)
Number of subjects: 67
Study 15986589 — intervention group
Group type: COMPARATOR
Intervention: Tilt-table test (TT)
Number of subjects: 67
Study 12653814 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 405
Study 12653814 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 405
Study 10337657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 3 months
Number of subjects: 259
Study 10337657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 6 months
Number of subjects: 259
Study 10337657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 3 months (clinical C)
Number of subjects: 259
Study 10337657 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen ablation for 6 months (clinical C)
Number of subjects: 259
Study 10337657 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 259
Study 7475139 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 149
Study 7475139 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 149
Study 7475139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 1683192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine, 50 mg qhs
Number of subjects: 15
Study 1683192 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine, 60 mg bid
Number of subjects: 15
Study 1683192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Terfenadine
Number of subjects: 15
Study 1683192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 15
Study 6119776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine, 300 mg day-1 for 8 consecutive weeks
Number of subjects: 42
Study 31562043 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy (six cycles of intravenous vinorelbine 25 mg/m2 on days 1, 8, and 15, and daily oral cyclophosphamide 25 mg/m2 on days 1-28)
Number of subjects: 371
Study 31562043 — intervention group
Group type: COMPARATOR
Intervention: No maintenance chemotherapy (control group)
Number of subjects: 371
Study 31562043 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy
Number of subjects: 371
Study 30278489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg (D1)
Number of subjects: 90
Study 30278489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg (D2)
Number of subjects: 90
Study 30278489 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 90
Study 26587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Midvastus approach (MV)
Number of subjects: 21
Study 26587881 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial parapatellar approach (MPP)
Number of subjects: 21
Study 26587881 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study 24468269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG-RIVM strain
Number of subjects: 60
Study 22456382 — intervention group
Group type: EXPERIMENTAL
Intervention: VASER-assisted lipoplasty
Number of subjects: 20
Study 22456382 — intervention group
Group type: COMPARATOR
Intervention: Suction-assisted lipoplasty
Number of subjects: 20
Study 20849317 — intervention group
Group type: EXPERIMENTAL
Intervention: iopromide 370
Number of subjects: 297
Study 20849317 — intervention group
Group type: COMPARATOR
Intervention: iomeprol 400
Number of subjects: 297
Study 17441846 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test with 15 microg Ni/cm(2) on large area
Number of subjects: 20
Study 17441846 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated open application test (ROAT) with 6.64 microg Ni/cm(2) on large area
Number of subjects: 20
Study 17441846 — intervention group
Group type: EXPERIMENTAL
Intervention: ROAT threshold
Number of subjects: 20
Study 17441846 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch test at higher concentrations of nickel
Number of subjects: 20
Study 14674041 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS of the lentiform nucleus in IPDUS patients
Number of subjects: 25
Study 14674041 — intervention group
Group type: COMPARATOR
Intervention: MRS of the lentiform nucleus in healthy volunteers (control)
Number of subjects: 25
Study 14674041 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS of the lentiform nucleus ipsilateral to the symptomatic side of the patient
Number of subjects: 25
Study 11692906 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (intravenous infusion)
Number of subjects: 20
Study 11692906 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (oral)
Number of subjects: 20
Study 9164906 — intervention group
Group type: EXPERIMENTAL
Intervention: Single coil
Number of subjects: 100
Study 9164906 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple coils
Number of subjects: 100
Study 8170842 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased skin wetness
Number of subjects: 1601
Study 8170842 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased skin pH
Number of subjects: 1601
Study 8170842 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized increases in both skin wetness and skin pH
Number of subjects: 1601
Study 3266379 — intervention group
Group type: COMPARATOR
Intervention: ketorolac placebo/heparin placebo
Number of subjects: 12
Study 3266379 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac active/heparin placebo
Number of subjects: 12
Study 3266379 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac active/heparin active
Number of subjects: 12
Study 3266379 — intervention group
Group type: COMPARATOR
Intervention: ketorolac placebo/heparin active
Number of subjects: 12
Study 3266379 — intervention group
Group type: EXPERIMENTAL
Intervention: heparin
Number of subjects: 12
Study 3266379 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac
Number of subjects: 12
Study 29771687 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine ER/ChEI
Number of subjects: 0
Study 29771687 — intervention group
Group type: COMPARATOR
Intervention: Placebo/ChEI
Number of subjects: 0
Study 27111239 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) 10 mg/day
Number of subjects: 428
Study 27111239 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 428
Study 25503557 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone (control group)
Number of subjects: 93
Study 25503557 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg fentanyl (fent1 group)
Number of subjects: 93
Study 25503557 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 µg/kg fentanyl (fent2 group)
Number of subjects: 93
Study 22642686 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group (4 weeks of heavy load squat strength training)
Number of subjects: 12
Study 22642686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 20716717 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Monitoring (HM)
Number of subjects: 1339
Study 17620645 — intervention group
Group type: EXPERIMENTAL
Intervention: Household-based water treatment interventions
Number of subjects: 492
Study 17620645 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 492
Study 16302899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 880
Study 16302899 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 880